The amyloid cascade hypothesis has been the dominant paradigm for drug discovery for AD, but recent advances in the understanding of tau biology in neurodegenerative diseases and difficulties of amyloid-directed immunotherapeutics have heightened interest in tau as a target for drug discovery [2–7], particularly tau oligomers [8, 9]. This evidence concerns the gene MAPT and neurodegenerative disease.